39
1
1
193
Cat. No. | Product Name | ||
---|---|---|---|
L8400 | 血液病分子库 | 514 compounds | |
514 种造血系统疾病相关的生物活性小分子化合物的特有集合,用于高通量、高内涵筛选; |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1687L |
CEF20 acetate(153045-21-7 free base)
|
Others | Others |
CEF20 acetate(153045-21-7 free base) 是 CEF 对照肽库,是来自巨细胞病毒 pp65 (495-503) 的 HLA-A*0201 限制性表位。 | |||
TP1543L |
G280-9 acetate(156761-76-1 free base)
|
Others | Others |
G280-9 acetate(156761-76-1 free base) 是一种常见的黑色素瘤 gp100 表位,受 MHC 相关 HLA-A2 限制。 G280-9 序列是独特的,因为它可以在非常低的浓度下被细胞毒性 T 淋巴细胞识别,但是它显示出低的总免疫原性,这可能是由于该肽对 HLA-A2 的亲和力相对较低。 | |||
TP1822L |
CEF6 acetate(913545-15-0 free base)
|
Influenza Virus | Microbiology/Virology |
CEF6 acetate(913545-15-0 free base) 是 HLA-B7限制性流感病毒核蛋白表位,属于 CEF 对照肽。 CEF 对照肽长度为 8-12 个氨基酸,其序列来自人类巨细胞病毒、爱泼斯坦-巴尔病毒和流感病毒。 | |||
TP1806L |
BCMA72-80 acetate(2293841-58-2 free base)
|
Others | Others |
BCMA72-80 acetate(2293841-58-2 free base) 是一种 HLA-A2 特异性 B 细胞成熟抗原 (BCMA) 肽。它用于研究表达 B 细胞成熟抗原的多发性骨髓瘤和肿瘤。 | |||
TP1527 |
CEF8, Influenza Virus NP (383-391)
CEF8, Influenza Virus NP 383-391 |
Others | Others |
CEF8, Influenza Virus NP (383-391) 是一种甲型流感病毒核蛋白,含有 383-391 残基,是甲型流感病毒核蛋白中重要的 HLA-B*2705 限制性表位,与细胞毒性 T 淋巴细胞介导的免疫逃逸有关。 | |||
T22297 |
Clindamycin hydrochloride monohydrate
Clindamycin alcoholate |
Antibiotic | Microbiology/Virology |
Clindamycin hydrochloride monohydrate(Clindamycin alcoholate)是一种口服蛋白质合成抑制剂,具有在金黄色葡萄球菌中以亚抑制浓度(sub-MICs)抑制毒力因子表达的能力。其抗性来源于50S核糖体亚基(23S rRNA)的抗生素结合位点通过酶促甲基化。此外,Clindamycin hydrochloride monohydrate能显著减少杀白细胞毒素(PVL)、毒性休克-葡萄球菌毒素(TSST-1)或α-溶血素(Hla)的产生。 | |||
T40590 |
NY-ESO-1 (87-111)
|
||
NY-ESO-1 (87-111) is a pan-MHC class II-restricted peptide that interacts with various HLA-DR and HLA-DP4 molecules, inducing activation of CD4+ T cells with Th1-type and Th-2/Th0-type responses, when presented in conjunction with HLA-DR and HLA-DP4 molecules. | |||
T80962 |
TPNQRQNVC
LRH-1 peptide |
||
TPNQRQNVC为HLA-B0702的九肽抗原决定簇,能激活CD8+ T细胞的免疫响应。 | |||
T80857 |
VLHDDLLEA
|
||
VLHDDLLEA是从MHC复合体HLA-A*0201分子中分离得到的多肽,具有被HLA-A*0201-限制性细胞毒T细胞(CTLs)识别的特性。该多肽可应用于移植物抗宿主病(GvHD)的研究。 | |||
TP1515 |
HPV16-E711-20 epitope
|
||
HPV16-E711-20 epitope is a well-known HLA-A*0201-restricted human cytotoxic T lymphocyte (CTL) epitope of the HPV16 E7 protein that shows high-affinity binding to HLA-A2 in vitro. | |||
TP1806 |
BCMA72-80
|
||
BCMA72-80 is a HLA-A2-specific B-cell maturation antigen (BCMA) peptide, with a strong affinity to HLA-A2. It is used to used in the research of multiple myeloma or other B-cell maturation antigen expressing tumors. | |||
TP1502 |
MAGE-A3 (195-203)
MAGE-A3 195-203 |
||
This peptide MAGE-3-encoded HLA-A24 epitope is a high MHC binder.The identification of this MAGE-3/HLA-A24 peptide may as a result effectiveially offer the opportunities to design peptide-based immunotherapeutic approaches that might prove to be potent in | |||
TP1543 |
G280-9
|
||
The G280-9 peptide, a common melanoma gp100 epitope restricted by MHC-associated HLA-A2. The G280-9 sequence is unique because it could be recognized by cytotoxic T lymphocytes at very low concentrations, however it shows low total immunogenicity that may | |||
TP1574 |
Gp100 (619-627)
Gp100 619-627 |
||
This is a HLA-A*0201 restricted epitope used in melanoma studies. | |||
TP1267 |
CEF27, Epstein-Barr Virus BRLF-1 lytic (148-156)
CEF27,Epstein-Barr Virus BRLF-1 lytic 148-156 |
||
HLA-A*0301-restricted epitope from Epstein-Barr Virus , EBV BRLF-1 (148-156). | |||
T80911 |
Tyrosinase (192-200), human mouse
|
||
Tyrosinase(192-200), human mouse 为九肽化合物,能被HLA-B44分子所识别的细胞溶解T细胞(CTL)所识别,常用于黑色素瘤相关癌症研究。 | |||
TP1525 |
HPV16 E7 (86-93) (TFA)(160212-93-1,free)
HPV16 E7 (86-93) (TFA) |
||
HPV16 E7 (86-93) TFA is a human leukocyte antigen (HLA)-A2.1 restricted HPV16 E7-derived peptide. | |||
TP1687 |
CEF20
|
||
CEF20, a CEF control peptide pool, is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503). | |||
T76015 |
HPV16 E7 (86-93) (TFA)
|
||
HPV16 E7 (86-93) TFA,一种HLA-A2.1限制的HPV16 E7衍生肽,在宫颈癌中显示出免疫原性。 | |||
TP1822 |
CEF6
|
||
CEF6, a HLA-B7 restricted influenza virus nucleoprotein epitope, belongs to the CEF control peptides. The CEF control peptides are 8-12 amino acids in length, with sequences derived from the human cytomegalovirus, Epstein-Barr virus and influenza virus. | |||
T81011 |
Tetanus Toxin (830–844)
|
||
Tetanus Toxin (830–844) 是具有生物活性的肽类化合物。它是破伤风毒素衍生的 TT830–844 CD4+ T 细胞表位,能与多种 HLA-DRB 分子结合。该 CD4+ T 细胞表位由于与广泛的 HLA-DRB 分子具有亲和力,有潜力在大范围人群中诱发 CD4+ T 细胞应答。 | |||
TP1717 |
CEF1, Influenza Matrix Protein M1 (58-66)
CEF1, Influenza Matrix Protein M1 58-66 |
||
CEF1, Influenza Matrix Protein M1 (58-66) is an epitope derived from the matrix protein of the influenza A virus.GILGFVFTL is a HLA-A2-restricted epitope from influenza matrix M1 protein. | |||
T76410 |
Tyrosinase (206-214), human
|
||
Tyrosinase(206-214), human (AFLPWHRLF),一种由9个氨基酸组成的肽,为酪氨酸酶的表位。可被HLA-A24限制性肿瘤浸润淋巴细胞(TIL)识别的Tyrosinase(206-214), human,具有重要生物医学意义。 | |||
T81423 |
Polzastobart
JTX 8064 |
||
Polzastobart (JTX-8064) 为一种人源化IgG4单克隆抗体,特异性与LILRB2结合,阻断其与配体及MHC I分子(经典与非经典)的相互作用。此抗体通过抑制LILRB2与HLA-A/B和/或HLA-G(癌细胞免疫耐受的标志)的结合,可增强巨噬细胞产生促炎细胞因子。Polzastobart 作为巨噬细胞免疫检查点抑制剂发挥作用。 | |||
T25051 |
Allotrap
Peptide Bc-1nl |
||
Allotrap is a small synthetic peptide derived from the alpha1 helix of the heavy chain of HLA class I proteins. It suppresses human T cell responses in vitro. It prolongs allograft survival in rats and mice. | |||
T74907 | ODN 21595 | ||
ODN 21595是一种鸟嘌呤修饰的抑制性寡核苷酸(INH-ODN)。该化合物能够抑制IFN-α和IL-6的释放,同时不具有细胞毒性。它还能降低CD86与HLA-DR的表达,显示出对于研究系统性红斑狼疮(SLE)具有潜力。 | |||
T76519 |
HCV Peptide (35-44)
|
||
HCVPeptide (35-44)为HCV核心蛋白的35至44位段,具有HLA-A2限制性CTL表位功能。该肽段通过KIR2DL2/3直接抑制NK细胞活性,以及协同CD94:NKG2A受体抑制NK细胞活性。 | |||
TP1554 |
HPV16 E7 (86-93)
|
||
This is amino acids 86 to 93 fragment of the human papilloma virus (HPV) type 16 oncoprotein E7. This HPV16-encoded peptide has very high affinity of binding to the HLA-A*0201 molecule.This immunogenic fragment may be used in vaccines for the prevention a | |||
T81431 |
Pol (476-484), HIV-1 RT Epitope
|
||
Pol (476-484),HIV-1RT Epitope 是具有生物活性的肽,对应逆转录酶 (RT) 的主要HLA A*0201限制性表位(Pol 残基 476-484)。其在HIV-1 RT中的角色涉及分析CTL逃逸机制。实际表位IV9在HIV-1感染的细胞系中被加工和呈现。 | |||
T39067 |
MAGE-3 (271-279)
|
||
MAGE-3 (271-279) is a peptide consisting of 271-279 amino acid residues that is derived from melanoma antigens encoded by the MAGE-3 gene. It is specifically recognized by cytolytic T lymphocytes (CTLs) and binds to the human leukocyte antigen (HLA)-A2 molecule. MAGE-3 is highly expressed in various human tumor types, such as malignant melanoma, but not in normal tissues, except for the testis and placenta. | |||
TP2142 |
CLIP (86-100) (TFA) (648881-58-7 free base)
CLIP (86-100) (TFA) |
Others | Others |
CLIP (86-100) TFA is amino acids 86 to 100 fragment of class II-associated invariant chain peptide (CLIP). CLIP is a small self-peptide and cleavage product of the invariant chain that resides in the HLA-II antigen-binding groove. | |||
T14205 |
AM679
|
Others | Others |
AM679 is a potent and selective FLAP inhibitor with IC50s of 2.2 nM/0.6 nM/154 nM for FLAP binding/hLA/hWB respectively. IC50 value: 2.2 nM/0.6 nM/154 nM(FLAP binding/hLA/hWB) [1] AM679 showed an improved CYP inhibition profile (IC50 3A4 = 16.7 lM, 2C9 = | |||
T74915 |
ODN D-SL03
|
||
ODN D-SL03是C类CpG寡核苷酸,能诱导PBMCs产生高水平IFN-α,激活人B细胞、NK细胞和单个核细胞,同时上调PBMCs亚群表面CD80、CD86和HLA-DR的表达,还能抑制肿瘤生长。ODN D-SL03序列:5'-tcgcgaacgttcgccgcgttcgaacgcgg-3'。 | |||
T76973 | Tosatoxumab | ||
Tosatoxumab (AR-301; KBSA301) 为一种人源化免疫球蛋白G1类单克隆抗体,专一性地中和金黄色葡萄球菌α毒素(α-溶血素; Hla),通过与该毒素N末端表位结合,防止其功能性毒素孔的寡聚化。此抗体对于金黄色葡萄球菌引起的肺炎,作为传统抗生素疗法的辅助,展现出被动免疫治疗的潜力。 | |||
T76985 | Tebotelimab | ||
Tebotelimab (MGD-013) 是一种人源的 IgG4κ 双特异性 PD-1/LAG-3双亲和再靶向 (DART) 抗体。Tebotelimab 结合 NS0 细胞表面表达的 PD-1和 LAG-3,EC50分别为 1.65 nM 和 0.41 nM。Tebotelimab 阻断 PD-1/PD-L1、PD-1/PD-L2 和 LAG-3/HLA (MHC-II) 相互作用和 PD-1信号。Tebotelimab 可恢复耗尽的 T 细胞功能并增强抗肿瘤免疫力。 | |||
T83695 |
MOG Peptide (human, bovine) acetate
Myelin Oligodendrocyte Glycoprotein Peptide |
||
Myelin Oligodendrocyte Glycoprotein (MOG) peptide 是 MOG 的一种内源性肽段截取,存在于髓鞘的细胞外表面。当与抗原血清型HLA-DR2结合时,MOG peptide 在通过中脑动脉阻塞(MCAO)诱导的缺血性中风模型中,能减少皮层和纹状体梗死体积,降低管-角转测试中的感觉运动障碍,增加对新奇气味的探索时间,以及增加雌性(但不是雄性)小鼠对笼伴侣发出的呼叫持续时间。 | |||
T81825 |
Melan-A/MART-1 analog
[Leu27]-Melan-A, MART-1 (26-35) |
||
[Leu27]-Melan-A, MART-1 (26-35)是一种具有改良的HLA-A*0201结合能力和增强的免疫原性及抗原性的生物活性肽。该类似物在第27位的Leu替换了Ala,与原生Melan-A (26-35)相比表现出更佳的性能。当序列N端为谷氨酰胺(Q)或谷氨酸(E)时,肽可能会自发形成焦谷氨酰(pGlu)。Q或E到pGlu的转化是自然发生的,pGlu的疏水性γ-内酰胺环被认为可增强针对胃肠道蛋白酶的抵抗力,使得含pGlu的肽成为这类肽的正常子集,在HPLC分析中通常作为评估肽纯度的一部分。 | |||
T76843 | Tebentafusp | ||
Tebentafusp (IMCgp100) 是靶向 gp100(一种黑色素瘤相关抗原)的双特异性融合蛋白。该药物通过其 T 细胞受体 (TCR) 高亲和力结合域以及抗 CD3 T 细胞接合域,指引 T 细胞针对表达 gp100 的肿瘤细胞进行杀伤。进一步,Tebentafusp 促进炎症细胞因子和细胞溶解酶的释放,直接导致肿瘤细胞裂解。 | |||
T83852 |
EGFRvIII Peptide TFA
PEGFRvIII (9-mer),Epidermal Growth Factor Receptor Variant III Peptide |
||
EGFRvIII peptide是一种合成肽,对应于特异性肿瘤、具有持续激活性的EGFR变体EGFRvIII的融合接头,该变体缺少野生型EGFR的第6至273个氨基酸。在25 µg/ml的浓度下,它能与MHC I类亚型HLA-A*0201阳性的T2细胞结合。在用于分离的人外周血单个核细胞(PBMCs)衍生的树突状细胞中,EGFRvIII peptide可诱导抗原呈递,进而刺激CD8+细胞毒性T淋巴细胞的激活和IFN-γ产生。与toll样受体5(TLR5)激动剂鞭毛蛋白B共同免疫EGFRvIII peptide(15 µg/动物),在正交GL261胶质母细胞瘤小鼠异种移植模型中,增加了CD8+ T细胞数量,减少了调节性T细胞(Tregs)数量,减少了肿瘤体积,并提高了生存率。 |
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T5S1981 |
alpha-Cyperone
(+)-α-Cyperone,α-香附酮,α-Cyperone |
Others; Endogenous Metabolite | Metabolism; Others |
alpha-Cyperone (α-Cyperone) 与 IL-6, Cox-2, Cdc42, Nck-2, Rac1 的表达下调相关,从而能够抑制炎症反应。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPK-01494 |
HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Tetramer Protein, Human, MHC (His & Avi)
HLA-A,HLA-A... |
Human | HEK293 Cells |
Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. | |||
TMPK-01496 |
HLA-A*01:01&B2M&CT83 (NTDNNLAVY) Monomer Protein, Human, MHC (His & Avi)
HLA-A,CT83,HLA-... |
Human | HEK293 Cells |
Cancer/testis antigens 83 (CT83), also called KK-LC-1 or CXorf61, recognized by cytotoxic T lymphocytes (CTL), has become a promising target for immunotherapy. | |||
TMPK-01409 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
Peptide Ready,MHC,HLA-A |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01426 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A*02:01,Peptide Read... |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01410 |
Peptide Ready HLA-A*24:02&B2M Monomer Protein, Human, MHC (His & Avi)
HLA-A,MHC,Peptide Ready |
Human | HEK293 Cells |
Peptide Ready HLA-G&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-G. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01415 |
APC-equivalent Peptide Ready HLA-A*02:01&B2M Tetramer Protein, Human, MHC (His)
Peptide Ready,HLA-A*02:0... |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Tetramer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01419 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Rea |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01422 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*... |
Human | HEK293 Cells |
Peptide Ready HLA-A*02:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01473 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
CT1.3,MAGE-3,MZ2-D,MZ2D,HLA-A... |
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01420 |
Peptide Ready HLA-A*03:01&B2M Monomer Protein, Human, MHC (His & Avi)
Peptide Ready,MHC,HLA-A*... |
Human | HEK293 Cells |
Peptide Ready HLA-A*03:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*03:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01425 |
Peptide Ready HLA-A*11:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HLA-A*02:01,Peptide Rea |
Human | HEK293 Cells |
Peptide Ready HLA-A*11:01&B2M Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*11:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01472 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Tetramer Protein, Human, MHC (His & Avi)
MAGE-3,CT1.3,Melanoma-as... |
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01421 |
Peptide Ready HLA-A*02:01&B2M Monomer Protein, Human, MHC (His & Avi), Biotinylated
HLA-A*02:01,MHC,Peptide Rea |
Human | HEK293 Cells |
HLA-A*02:01&B2M&Peptide ready Monomer is absent from peptide, namely peptide-receptive MHC. It can be loaded with antigenic peptides matching HLA-A*02:01. Peptide ready MHC molecules comprising human HLA alleles and B2M, which can be readily tetramerized and loaded with peptides of choice in a high-throughput manner. | |||
TMPK-01508 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein, Human, MHC (His & Avi)
TP53,Antigen NY-CO-13,P53,MHC,HLA... |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01476 |
HLA-A*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer Protein, Human, MHC (His & Avi)
HLA-A*24:02,P100,Glycoprotein 100... |
Human | HEK293 Cells |
Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100. | |||
TMPK-01475 |
HLA-A*24:02&B2M&GP100 Intron 4 (VYFFLPDHL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
HLA-A*24:02,Intron 4,gp100,GP100 ... |
Human | HEK293 Cells |
Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100. | |||
TMPK-01442 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
HLA-A,P53,TP53,LFS1,MHC,BCC7,TRP5... |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01509 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein, Human, MHC (His & Avi)
TRP53,HLA-A,TP53,LFS1,P53,MHC,FLJ... |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01531 |
HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer Protein, Human, MHC (His & Avi)
Antigen NY-CO-13,MHC,FLJ92943,TRP53,HLA |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01532 |
HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer Protein, Human, MHC (His & Avi)
Antigen NY-CO-13,BCC7,FLJ92943,HLA |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01552 |
HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Monomer Protein, Human, MHC (His & Avi), Biotinylated
TP53,TRP53,HLA-A,MHC,Ant... |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01538 |
HLA-A*02:01&B2M&P53 WT (HMTEVVRRC) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,LFS1,Antigen NY-CO-13,HLA- |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein. p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPK-01437 |
HLA-A*02:01&B2M&P53 R175H (HMTEVVRHC) Tetramer Protein, Human, MHC (His & Avi), PE-Labeled
FLJ92943,HLA-A,TP53,Anti... |
Human | HEK293 Cells |
p53 is a tumor suppressor protein. Under stressful conditions, p53 tightly regulates cell growth by promoting apoptosis and DNA repair. When p53 becomes mutated, it loses its function, resulting in abnormal cell proliferation and tumor progression. Depending on the p53 mutation, it has been shown to form aggregates leading to negative gain of function of the protein.p53 mutant associated aggregation has been observed in several cancer tissues and has been shown to promote tumor growth. | |||
TMPH-01485 |
HLA-A Protein, Human, Recombinant (His)
|
Human | E. coli |
HLA-A Protein, Human, Recombinant (His) is expressed in E. coli. | |||
TMPK-01520 |
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Tetramer Protein, Human, MHC (His & Avi)
Alpha-1-fetoprotein,AFP,HPA |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01519 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi)
MHC,FETA,AFP,Alpha-feto,... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01501 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Tetramer Protein, Human, MHC (His & Avi)
MHC,Hepatitis B virus,HBV |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01484 |
HLA-A*02:03&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi)
HPAFP,FETA,AFP,AFPD,... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01521 |
HLA-A*02:01&B2M&AFP (PLFQVPEPV) Monomer Protein, Human, MHC (His & Avi)
MHC,Alpha-feto,AFPD,Alph... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01515 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi)
HPAFP,Alpha-fetoprotein,MHC,FET |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01455 |
HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Monomer Protein, Human, MHC (His & Avi)
OIP4,PRAME,OIP-4,MAPE |
Human | HEK293 Cells |
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. | |||
TMPK-01492 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi)
Hepatitis B virus,HBV,MHC |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01517 |
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Monomer Protein, Human, MHC (His & Avi)
survivin variant 3 alpha... |
Human | HEK293 Cells |
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. | |||
TMPK-01454 |
HLA-A*02:01&B2M&PRAME (SLLQHLIGL) Tetramer Protein, Human, MHC (His & Avi)
MAPE,OIP4,OIP-4,PRAME |
Human | HEK293 Cells |
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. | |||
TMPK-01516 |
HLA-A*02:01&B2M&Survivin (LMLGEFLKL) Tetramer Protein, Human, MHC (His & Avi)
IAP4,survivin variant 3 a |
Human | HEK293 Cells |
Survivin (also known as BIRC5) is an evolutionarily conserved eukaryotic protein that is essential for cell division and can inhibit cell death. Normally it is only expressed in actively proliferating cells, but is upregulated in most, if not all cancers; consequently, it has received significant attention as a potential oncotherapeutic target. | |||
TMPK-01540 |
HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Tetramer Protein, Human, MHC (His & Avi)
HLA0201,P100,MHC I,gp100,Glycoprotein 100,... |
Human | HEK293 Cells |
Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100. | |||
TMPK-01551 |
HLA-A*02:01&B2M&GP100 (YLEPGPVTA) Monomer Protein, Human, MHC (His & Avi)
MHC I,ME20-M,Glycoprotein 100,gp100,P100,HLA |
Human | HEK293 Cells |
Glycoprotein 100, gp100 or Melanocyte protein PMEL is 661 amino acids long and is a type I transmembrane glycoprotein enriched in melanosomes, which are the melanin-producing organelles in melanocytes. This protein is involved in melanosome maturation. The Human HLA-A*0201 gp100 (YLEPGPVTA) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and YLEPGPVTA peptide of the gp100. | |||
TMPK-01482 |
HLA-A*02:03&B2M&AFP (FMNKFIYEI) Tetramer Protein, Human, MHC (His & Avi)
MHC,AFPD,Alpha-fetoprotein,FET |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
TMPK-01503 |
HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Monomer Protein, Human, MHC (His & Avi)
Macropain chain 7,LMP-2,RING12,LM... |
Human | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01441 |
HLA-A*02:01&B2M&PRAME (ALYVDSLFFL) Monomer Protein, Human, MHC (His & Avi)
OIP-4,PRAME,MAPE,OIP4 |
Human | HEK293 Cells |
PRAME (PReferentially expressed Antigen in MElanoma) is a melanoma-associated antigen expressed in cutaneous and ocular melanomas and some other malignant neoplasms, while its expression in normal tissue and benign tumors is limited. | |||
TMPK-01533 |
HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Monomer Protein, Human, MHC (His & Avi)
MHC,LMP2,RING12,PSMB9,Macropain cha |
Human | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01542 |
HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Tetramer Protein, Human, MHC (His & Avi)
RMF,PSMB9,Proteasome chain 7,RING12,LMP2,L... |
Human | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-01485 |
HLA-A*01:01&B2M&DSG3 (YTDNWLAVY) Monomer Protein, Human, MHC (His & Avi)
CDHF6,DG3,DSG3,PVA,DSG-3,Desmoglein-3 |
Human | HEK293 Cells |
DSG3 is overexpressed in head neck cancer and is a potential molecular target for inhibition of oncogenesis. DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. These findings suggest that DSG3 is a potential molecular target in the development of adjuvant therapy for HNC. | |||
TMPK-01498 |
HLA-A*11:01&B2M&LMP2 (SSCSSCPLTK) Tetramer Protein, Human, MHC (His & Avi)
Proteasome chain 7,MHC,RING12,RMF,LMP2,LMP... |
Human | HEK293 Cells |
The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor, implicating an important role of LMP2 in regulating cell growth of ma... | |||
TMPK-00650 |
HLA-A*02:01 & B2M & MART-1 (ELAGIGILTV) Monomer Protein, Cynomolgus, Recombinant (His)
IL10A,GVHDS,IL-10,MGC126451,B-TCGF,MGC126450,TGIF,C... |
Cynomolgus | HEK293 Cells |
Interleukin 10 (IL10) is a key anti-inflammatory cytokine that can inhibit proinflammatory responses of both innate and adaptive immune cells. An association between IL10 and intestinal mucosal homeostasis became clear with the discovery that IL10 and IL10 receptor (IL10R)-deficient mice develop spontaneous intestinal inflammation. Similarly, patients with deleterious mutations in IL10, IL10RA, or IL10RB present with severe enterocolitis within the first months of life. HLA-A*02:01 & B2M & MART-... | |||
TMPK-01474 |
HLA-A*24:02&B2M&MAGE-A3 (IMPKAGLLI) Monomer Protein, Human, MHC (His & Avi)
|
Human | HEK293 Cells |
Melanoma antigen gene A3 (MAGE-A3) is one of the most immunogenic cancer testis antigens and is common in various types of cancers. MAGE-A3 can be considered as a predictor for poor prognosis and an option for vaccine immunotherapy in patients with PCa. | |||
TMPK-01444 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Tetramer Protein, Human, MHC (His & Avi)
MZ2-E,MAGE1A,MAGE-1 anti... |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01446 |
HLA-A*02:01&B2M&MAGE-A1 (KVLEYVIKV) Monomer Protein, Human, MHC (His & Avi)
MAGE1,MAGE1A,MAGE-1 ... |
Human | HEK293 Cells |
MAGE-A1 belongs to the chromosome X-clustered genes of cancer-testis antigen family and is normally expressed in the human germ line but is also overexpressed in various tumors. | |||
TMPK-01491 |
HLA-A*02:01&B2M&HBV (FLLTRILTI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
MHC,HBV,Hepatitis B virus |
Human | HEK293 Cells |
Hepatitis B virus (HBV), is the leading cause of liver diseases infecting an estimated 240 million persons worldwide. The HBV prevalence rates are variables between different countries, with an high level of endemicity in the south-eastern part of Europe. Seven main HBV-D subgenotypes have been described until now (D1-D7). | |||
TMPK-01477 |
HLA-A*02:01&B2M&AFP (FMNKFIYEI) Monomer Protein, Human, MHC (His & Avi), Biotinylated
HPAFP,FETA,Alpha-1-fetop... |
Human | HEK293 Cells |
Alpha-fetoprotein (AFP), a specific liver cancer marker, T cells expressing AFP-CAR selectively degranulated, released cytokines, and lysed liver cancer cells that were HLA-A*02:01 /AFP while sparing cells from multiple tissue types that were negative for either expressed proteins.CAR T-cell immunotherapy targeting intracellular/secreted solid tumor antigens can elicit a potent antitumor response. | |||
------------------------ 更多 ------------------------ |